WALTHAM,
Mass., Feb. 7, 2025 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
clinical-stage biotechnology company utilizing best-in-class
antibody engineering, rational therapeutic combinations, and
precision medicine approaches to target improved efficacy and
convenience in the treatment of IBD and other immune-mediated
diseases, today announced that Spyre's independent Compensation
Committee of the Board of Directors approved the grant of stock
options to purchase 35,000 shares of common stock of Spyre to three
non-executive employees as equity inducement awards under the Spyre
Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the
"2018 Plan"). The stock options were approved on February 3, 2025 and were material to each
employee's acceptance of employment with Spyre, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an
exercise price equal to $22.65, the
closing price per share of Spyre's common stock as reported by
Nasdaq on February 3, 2025. The
options granted to each employee shall vest and become exercisable
as to one-fourth (1/4th) of the shares subject to the respective
options on the first anniversary of the employee's start date, and
one-forty-eighth (1/48th) of the shares subject to the respective
options shall vest and become exercisable monthly thereafter, in
each case, subject to continuous service with Spyre through the
applicable vesting dates. The stock options are subject to the
terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation inflammatory bowel disease
(IBD) and other immune-mediated disease products by combining
best-in-class antibody engineering, rational therapeutic
combinations, and precision medicine approaches. Spyre's pipeline
includes investigational extended half-life antibodies targeting
α4β7, TL1A, and IL-23. For more information, visit Spyre's website
at www.spyre.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-grants-of-inducement-awards-302371607.html
SOURCE Spyre Therapeutics, Inc.
